Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality... Show more
The Moving Average Convergence Divergence (MACD) for MDGL turned positive on June 03, 2025. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MDGL's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where MDGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 26, 2025. You may want to consider a long position or call options on MDGL as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
MDGL moved above its 50-day moving average on June 26, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 50-day moving average for MDGL moved below the 200-day moving average on June 23, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MDGL broke above its upper Bollinger Band on June 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MDGL entered a downward trend on June 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.398) is normal, around the industry mean (16.339). P/E Ratio (0.000) is within average values for comparable stocks, (58.407). MDGL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.310). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (20.661) is also within normal values, averaging (253.057).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
FIDU | 77.31 | 0.70 | +0.91% |
Fidelity MSCI Industrials ETF | |||
SPYV | 52.11 | 0.18 | +0.35% |
SPDR® Portfolio S&P 500 Value ETF | |||
IBTK | 19.79 | 0.03 | +0.13% |
iShares iBonds Dec 2030 Term Trsry ETF | |||
XDSQ | 37.38 | 0.01 | +0.03% |
Innovator US Eq Acltd ETF™ Quarterly | |||
PICB | 24.00 | -0.07 | -0.29% |
Invesco International Corporate Bond ETF |
A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.
Ticker / NAME | Correlation To MDGL | 1D Price Change % | ||
---|---|---|---|---|
MDGL | 100% | +0.45% | ||
KANT - MDGL | 62% Loosely correlated | +15.88% | ||
ALXO - MDGL | 56% Loosely correlated | -6.98% | ||
ZNTL - MDGL | 51% Loosely correlated | -6.35% | ||
CGEM - MDGL | 50% Loosely correlated | N/A | ||
NAGE - MDGL | 44% Loosely correlated | +2.89% | ||
More |